China's Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive sta
AstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as they build a case to challenge Gilead's already-markete
Roche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and "industrialised" drug discovery to find new neuroscience and cancer drugs.
Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<
BeyondSpring's hopes of an early Christmas gift from the FDA were dashed today after the regulator said it was unable to approve the company's lead drug plinabulin as a treatment for low wh
The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, after granting the application a priori